Kyowa Kirin Co., Ltd. (KYKOF)
| Market Cap | 7.74B +1.8% |
| Revenue (ttm) | 3.21B +3.2% |
| Net Income | 458.52M +41.8% |
| EPS | 0.88 +42.6% |
| Shares Out | n/a |
| PE Ratio | 16.87 |
| Forward PE | n/a |
| Dividend | 0.43 (2.84%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 35,316 |
| Average Volume | 3,690 |
| Open | 14.43 |
| Previous Close | n/a |
| Day's Range | 14.43 - 14.43 |
| 52-Week Range | 12.42 - 18.00 |
| Beta | 0.10 |
| RSI | 46.97 |
| Earnings Date | May 7, 2026 |
About Kyowa Kirin
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular... [Read more]
Financial Performance
In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.
Financial numbers in JPY Financial StatementsNews
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus da...
Kyowa Kirin downgraded to Sell from Buy at Citi
Citi downgraded Kyowa Kirin (KYKOF) to Sell from Buy with a 2,000 yen price target
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Shinichiro Muraoka downgraded Kyowa Kirin (KYKOF) to Underweight from Equal Weight with a 1,700 yen price target
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
SMBC Nikko downgraded Kyowa Kirin (KYKOF) to Neutral from Outperform with a 2,200 yen price target
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Kyowa Kirin (KYKOF) to Underweight from Neutral with a price target of 1,800 yen, down from 2,300 yen. The company announced it will discontinue all clinical trials for
Kyowa Kirin stops development of skin condition treatment
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
Kyowa Kirin (KYKOF) announced the discontinuation of all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being evaluated for potential indications in moderat...
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
Kyowa Kirin to regain control of rocatinlimab development, commercialization
Kyowa Kirin (KYKOF) announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program...
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Kyowa Kirin (KYKOF) to Sell from Neutral with a 2,250 yen price target The firm believes the company’s favorable medium-term earnings outlook is now largely priced in
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick,...
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for...
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceu...
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for pa...
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
– First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia – – First and only d...
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
Kura Oncology (KURA) and Kyowa Kirin (KYKOF) announced dosing of the first patient in a cohort of the KOMET-007 clinical trial. This cohort evaluates ziftomenib, a once-daily, investigational oral men...
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome First-of-its kind tool to guide HCPs on what to consider when staging patients...
Kyowa Kirin Earnings Call Transcript: Q2 2025
Revenue and profits declined year-over-year due to restructuring and special retirement costs, but key products like Crysvita and Poteligeo showed strong growth in North America and EMEA. R&D pipeline advanced with promising data for Ziftomenib and Rocatinlimab, and AI-driven strategies are boosting market penetration.
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO , July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
-Agreement extends one of the world's most enduring alliances for drug discovery- -Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to s...
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
PRINCETON, N.J. , Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the C...
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and development Longstanding relationship str...
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases w...
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.